Littérature scientifique sur le sujet « NSCLP »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Sommaire
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « NSCLP ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "NSCLP"
Machado, Renato Assis, Lilianny Querino Rocha de Oliveira, Ana Lúcia Carrinho Ayroza Rangel, Silvia Regina de Almeida Reis, Rafaela Scariot, Daniella Reis Barbosa Martelli, Hercílio Martelli-Júnior et Ricardo D. Coletta. « Brazilian Multiethnic Association Study of Genetic Variant Interactions among FOS, CASP8, MMP2 and CRISPLD2 in the Risk of Nonsyndromic Cleft Lip with or without Cleft Palate ». Dentistry Journal 11, no 1 (26 décembre 2022) : 7. http://dx.doi.org/10.3390/dj11010007.
Texte intégralSavitha, Sathyaprasad, S. M. Sharma, Shetty Veena et R. Rekha. « Single nucleotide polymorphism of bone morphogenetic protein 4 gene : A risk factor of non-syndromic cleft lip with or without palate ». Indian Journal of Plastic Surgery 48, no 02 (mai 2015) : 159–64. http://dx.doi.org/10.4103/0970-0358.163053.
Texte intégralGoldsberry, Grant, Dan O'Leary, Rich Hichwa et Peg Nopoulos. « Functional Abnormalities in the Neural Circuitry of Reading in Men with Nonsyndromic Clefts of the Lip or Palate ». Cleft Palate-Craniofacial Journal 43, no 6 (novembre 2006) : 683–90. http://dx.doi.org/10.1597/05-043.
Texte intégralXavier, D. L., Y. A. Arif, R. V. Murali, S. Kishore Kumar, S. Vipin Kumar, R. Tamang, K. Thangaraj et L. V. K. Bhaskar. « Analysis of Microsatellite Polymorphisms in South Indian Patients with Non Syndromic Cleft Lip and Palate ». Balkan Journal of Medical Genetics 16, no 1 (1 juin 2013) : 49–54. http://dx.doi.org/10.2478/bjmg-2013-0017.
Texte intégralAndrews-Casal, Melanie, Dennis Johnston, Jack Fletcher, John B. Mulliken, Samuel Stal et Jacqueline T. Hecht. « Cleft Lip with or without Cleft Palate : Effect of Family History on Reproductive Planning, Surgical Timing, and Parental Stress ». Cleft Palate-Craniofacial Journal 35, no 1 (janvier 1998) : 52–57. http://dx.doi.org/10.1597/1545-1569_1998_035_0052_clwowc_2.3.co_2.
Texte intégralOtero, Liliana, Luis Bermudez, Karina Lizarraga, Irene Tangco, Rocelyn Gannaban et Daniel Meles. « A Comparative Study of Facial Asymmetry in Philippine, Colombian, and Ethiopian Families with Nonsyndromic Cleft Lip Palate ». Plastic Surgery International 2012 (24 octobre 2012) : 1–6. http://dx.doi.org/10.1155/2012/580769.
Texte intégralKhan, Mahamad Irfanulla, Prashanth CS et Narasimhamurty Srinath. « Role of PAX7 Gene rs766325 and rs4920520 Polymorphisms in the Etiology of Non-syndromic Cleft Lip and Palate : A Genetic Study ». Global Medical Genetics 09, no 03 (15 juillet 2022) : 208–11. http://dx.doi.org/10.1055/s-0042-1748531.
Texte intégralAlam, Mohammad Khursheed, Ahmed Ali Alfawzan, Fatema Akhter, Haytham Jamil Alswairki et Prabhat Kumar Chaudhari. « Evaluation of Lip Morphology and Nasolabial Angle in Non-Syndromic Cleft Lip and/Palate and Non-Cleft Individuals ». Applied Sciences 12, no 1 (30 décembre 2021) : 357. http://dx.doi.org/10.3390/app12010357.
Texte intégralLiberton, Denise K., Payal Verma, Konstantinia Almpani, Peter W. Fung, Rashmi Mishra, Snehlata Oberoi, Figen Ç. Şenel et al. « Craniofacial Analysis May Indicate Co-Occurrence of Skeletal Malocclusions and Associated Risks in Development of Cleft Lip and Palate ». Journal of Developmental Biology 8, no 1 (28 janvier 2020) : 2. http://dx.doi.org/10.3390/jdb8010002.
Texte intégralNeela, Praveen Kumar, Gosla Srinivas Reddy, Akhter Husain, Vasavi Mohan, Sravya Thumoju et Rajeshwari BV. « Association of Single Nucleotide Polymorphisms on Locus 18q21.1 in the Etiology of Nonsyndromic Cleft Lip Palate (NSCLP) in Indian Multiplex Families ». Global Medical Genetics 08, no 01 (19 février 2021) : 024–31. http://dx.doi.org/10.1055/s-0041-1723087.
Texte intégralThèses sur le sujet "NSCLP"
Bianco, Anna Monica Rosaria. « Characterization of novel genes insolved in non syndromic cleft lip with or with out cleft palate (NSCLP) ». Doctoral thesis, Università degli studi di Trieste, 2010. http://hdl.handle.net/10077/3735.
Texte intégralNon-syndromic cleft lip with or without cleft palate (NSCLP) is one of the most common birth defect. Genetic studies on human populations have identified numerous predisposing factors, as MYH9 and JARID2, whose role during palatogenesis remains obscure. In order to improve our knowledge on pathogenetic mechanisms, we carried out expression studies during mouse palate development using RNA in situ hybridization. As reference genes (Tgfb3, Irf6, Pvrl1, Foxe1 and Tp63) known to be required for correct palate formation, Jarid2 and Myh9 are expressed in the epithelial cells of the palatine processes before and at the time of contact. Then, this signal decreases and eventually disappears concomitantly with the degradation of the medial epithelial cells. Consistent with these observations, RT-PCR carried out on dissected palatal shelves detected products of Myh9 and Jarid2 from embryonic day E14.0 to E15.0 with a pick at E14.5, the stage when shelves appose in the midline. Taken together, these expression studies strongly support the association studies that designate these genes as predisposing factors for NSCLP. In multifactorial diseases as NSCLP once genetic studies demonstrate association, a major challenge is to identify mutations. In this regard, we started analyzing two in linkage disequilibrium SNPs (rs3752462 of MYH9 and rs2076056 of JARID2) that could be involved in defective splicing mechanisms, as hypothesized on the basis of their localization within splice sites. Using a hybrid minigene assay, however, we demonstrated that none of the allelic variants lead to any aberrant products at least in HeLa cells, the model used for this study. Moreover, we investigated whether alternative splicing events of the Myh9 gene detected in cochlea and brain (Li et al., 2008) could also be found in other tissues and palate. A small insertion of 12 bp between exon 4 and 5 (loop1) due to an alternative splicing was detected in all adult tissues analyzed. The same insertion was not detected in embryonic tissues, such as palatal samples at different stages of development, and brain. These results suggest that the genomic region of loop1 should be investigated in all risk haplotypes to search for pathogenetic variants. In conclusion, further investigations should be planned to explore the role of MYH9 and JARID2 in orofacial development in order to dissect signaling pathways during palate formation and identify the causative variants contributing to NSCLP.
XXII Ciclo
1973
Krüger, Marcus. « Molekulare und funktionale Charakterisierung der neuronalen bHLH Transkritptionsfaktoren NSCL-1 und NSCL-2 ». [S.l.] : [s.n.], 2002. http://deposit.ddb.de/cgi-bin/dokserv?idn=969337183.
Texte intégralPegoraro, Ilan Emanuel Moreira. « NSCL in the ETSI M2M platform ». Master's thesis, Universidade de Aveiro, 2014. http://hdl.handle.net/10773/14704.
Texte intégralThe evolution of every day gadgets into smart-devices able to react to their surrounding environment is enabling the development of novel applications aiming revolutionize the industry related to this technology. Currently much attention has been given to standardizing IoT and M2M in order to build an interoperable foundation that will enable the growth of the future Internet, where devices will communicate without, or at least minimizing, human intervention. In this dissertation is presented in first place issues such as: heterogeneity, scalability, addressing and the first approach taken by the ETSI M2M standard. Subsequently, is presented the ETSI M2M vision and high-level architecture together with current work in this area. Finally an implementation of the network middleware is going to be presented along with further testing.
A evolução dos dispositivos do dia a dia em dispositivos inteligentes capazes de reagir ao ambiente que os rodeia está a permitir a criação de novas aplicações que visam revolucionar a industria. Atualmente tem-se dado muita atenção a estandardização da Internet das Coisas e comunicações máquinaa- máquina, com o objetivo de construir uma fundação interoperável que permitirá o crescimento futuro da Internet, onde os dispositivos irão comunicar sem, ou com mínima, intervenção humana. Nesta dissertação é apresentado em primeiro lugar requisitos como heterogeneidade, escalabilidade, endereçamento e a primeira abordagem feita pelo standard M2M do ETSI. Consequentemente, é a apresentada a visão e a arquitetura e o trabalho realizado nesta área. Por fim é apresentada a implementação da componente de rede realizada nesta dissertação juntamente com os respetivos testes.
Chater, Emily. « Novel therapeutic targets in NSCLC resistance to Erlotinib ». Thesis, Imperial College London, 2017. http://hdl.handle.net/10044/1/50699.
Texte intégralHolgersson, Georg. « Prognostic Factors in Non-Small Cell Lung Cancer (NSCLC) ». Doctoral thesis, Uppsala universitet, Experimentell och klinisk onkologi, 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-327925.
Texte intégralStamatkin, Christopher W. « PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) AS A THERAPEUTIC TARGET IN NSCLC ». UKnowledge, 2014. http://uknowledge.uky.edu/pharmacy_etds/58.
Texte intégralChatterjee, Saradiya. « Role of TLR7 in non-small cell lung carcinona (NSCLC) ». Paris 6, 2013. http://www.theses.fr/2013PA066063.
Texte intégralLung cancer accounts for over 1 million deaths per year with a 5-year survival of 8-12%. Stimulation of TLRs by the natural ligands like the PAMPs and DAMPs results in a proinflammatory signaling cascade. We have shown that stimulation of lung cancer cell lines with TLR7 agonist lead to tumor cell survival and chemoresistance in vitro. We studied the effect of TLR7 agonists on A549 and LL/2 cells injected in NOD/SCID and C57BL/6 mice either treated or not with cisplatin. Loxoribine has a pro-tumoral effect on A549 cells and induces chemoresistance in NOD/SCID mice. Blockade of TLR7 with IRS661 reversed the pro-tumoral effect of TLR7 agonist on A549 cells. CL264 was also found to have a pro-tumoral effect on LL/2 cells and induced chemoresistance in NOD/SCID mice. On the other hand CL264 at lower concentration induces an anti-tumoral effect on LL/2 cells while at a higher concentration demonstrated a pro-tumoral effect in C57BL/6 mice. We also demonstrated an overall bad prognostic value for higher expression of TLR7 by tumoral cells among NSCLC patients treated and not treated with neoadjuvant chemotherapy. These results suggest a pro- tumoral role and induction of chemoresistance by TLR7 in NSCLC patients. Use of TLR7 agonist as therapeutic option is recommended based on the TLR7 expression level for individual NSCLC patients. TLR7 antagonist holds promise for treatment of NSCLC in future
Recondo, Gonzalo. « Resistance Mechanisms to ALK Tyrosine Kinase Inhibitors (TKIs) in NSCLC ». Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS248/document.
Texte intégralThe molecular study and classification of lung adenocarcinomas has led to the development of selective targeted therapies aiming to improve disease control and survival in patients. The anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor from the insulin tyrosine kinase receptor family, with a physiologic role in neural development. Gene rearrangements involving the ALK kinase domain occur in ~3-6% of patients with lung adenocarcinoma. The fusion protein dimerizes leading to transactivation of the ALK kinase domain in a ligand-independent and constitutive manner. Lorlatinib is a third generation ALK inhibitor with high potency and selectivity for this kinase in vitro and in vivo, and elevated penetrance in the central nervous system. Lorlatinib can overcome resistance mediated by over 16 secondary kinase domain mutations occurring in 13 residues upon progression to first - and second - generation ALK TKI. In addition, treatment with lorlatinib is effective for patients who have been previously treated with a first and a second generation or a second generation ALK TKI upfront and is currently approved for this indication. The full spectrum of biological mechanisms driving lorlatinib resistance in patients remains to be elucidated. It has been recently reported that the sequential acquisition of two or more mutations in the kinase domain, also referred as compound mutations, is responsible for disease progression in about 35% of patients treated with lorlatinib, mainly by impairing its binding to the ALK kinase domain. However, the effect of these compound mutations on the sensitivity to the repertoire of ALK inhibitors can vary, and other resistance mechanisms occurring in most patients are unknown. My PhD thesis aimed at exploring resistance to lorlatinib in patients with ALK-rearranged lung cancer through spatial and temporal tumor biopsies and development of patient-derived models. Within the institutional MATCH-R study (NCT02517892), we performed high-throughput whole exome, RNA and targeted next-generation sequencing, together with plasma sequencing to identify putative genomic and bypass mechanisms of resistance. We developed patient-derived cell lines and characterized novel mechanisms of resistance and personalized treatment strategies in vitro and in vivo. We characterized three mechanisms of resistance in four patients with paired biopsies. We studied the induction of epithelial-mesenchymal transition (EMT) by SRC activation in a patient-derived cell line exposed to lorlatinib. Mesenchymal cells were sensitive to combined SRC and ALK co-inhibition, showing that even in the presence of an aggressive and challenging phenotype, combination strategies can overcome ALK resistance. We identified two novel ALK kinase domain compound mutations, F1174L/G1202R, C1156Y/G1269A, occurring in two patients treated with lorlatinib. We developed Ba/F3 cell models harboring single and compound mutations to study the differential effect of these mutations on lorlatinib resistance. Finally, we characterized a novel mechanism of resistance caused by NF2 loss of function at the time of lorlatinib progression through the development of patients derived PDX and cell lines, and in vitro validation of NF2 knock-out with CRISPR/CAS9 gene editing. Downstream activation of mTOR was found to drive lorlatinib resistance by NF2 loss of function and was overcome by providing treatment with mTOR inhibitors.This study shows that mechanisms of resistance to lorlatinib are more diverse and complex than anticipated. Our findings also emphasize how longitudinal studies of tumor dynamics allow deciphering TKI resistance and identifying reversing strategies
Baghai, Tabassom. « ATF3 as a Key Regulator of Cisplatin Cytotoxicity : Combining ATF3 Inducing Agents Enhances Cisplatin Activity in NSCLC ». Thesis, Université d'Ottawa / University of Ottawa, 2018. http://hdl.handle.net/10393/37963.
Texte intégralDaskalos, Alexandros. « Deregulation of DNA methylation aand retrotransposon reactivation in NSCL ». Thesis, University of Liverpool, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.539561.
Texte intégralLivres sur le sujet "NSCLP"
U.S. Army Chemical Materiel Destruction Agency., dir. Non-Stockpile Chemical Materiel Program : NSCMP. [Aberdeen Proving Ground, MD : U.S. Army Chemical Materiel Destruction Agency, 1995.
Trouver le texte intégralU.S. Army Chemical Materiel Destruction Agency., dir. Non-Stockpile Chemical Materiel Program : NSCMP. [Aberdeen Proving Ground, MD : U.S. Army Chemical Materiel Destruction Agency, 1995.
Trouver le texte intégralU.S. Army Chemical Materiel Destruction Agency, dir. Non-Stockpile Chemical Materiel Program : NSCMP. [Aberdeen Proving Ground, MD : U.S. Army Chemical Materiel Destruction Agency, 1995.
Trouver le texte intégralU.S. Army Chemical Materiel Destruction Agency, dir. Non-Stockpile Chemical Materiel Program : NSCMP. [Aberdeen Proving Ground, MD : U.S. Army Chemical Materiel Destruction Agency, 1995.
Trouver le texte intégralCappuzzo, Federico. Guide to Targeted Therapies : EGFR mutations in NSCLC. Cham : Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-03059-3.
Texte intégralKim, Ho-jung. array-CGH rŭl iyong han piso sepʻo pʻyeam ŭi chogi chaebal pʻyojija mit chindan mohyŏng kaebal = : Development of early-recurrence detection marker and diagnostic model using array-CGH in NSCLC. [Seoul] : Pogŏn Pokchibu, 2007.
Trouver le texte intégralCappuzzo, Federico. Guide to Targeted Therapies : EGFR mutations in NSCLC : EGFR mutations in NSCLC. Adis, 2014.
Trouver le texte intégralNon-Stockpile Chemical Materiel Program : NSCMP. [Aberdeen Proving Ground, MD : U.S. Army Chemical Materiel Destruction Agency, 1995.
Trouver le texte intégralKrawczyk, Paweł Adam, Qing Zhou, Rafal Dziadziuszko et Natasha Leighl, dir. Issues and Challenges in NSCLC Immunotherapy. Frontiers Media SA, 2021. http://dx.doi.org/10.3389/978-2-88971-816-0.
Texte intégralNorthumberland Strait Crossing Project (NSCP). [Washington, DC] : Federal Highway Administration, 1996.
Trouver le texte intégralChapitres de livres sur le sujet "NSCLP"
Shih, Helen. « BRAF in NSCLC ». Dans Targeted Therapies in Lung Cancer : Management Strategies for Nurses and Practitioners, 39–49. Cham : Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16550-5_5.
Texte intégralDu, Lingling, Saiama N. Waqar et Daniel Morgensztern. « Multimodality Therapy for NSCLC ». Dans Cancer Treatment and Research, 151–63. Cham : Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-40389-2_7.
Texte intégralCappuzzo, Federico. « Therapy options for advanced NSCLC ». Dans Guide to Targeted Therapies : Treatment Resistance in Lung Cancer, 5–25. Cham : Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-20741-4_2.
Texte intégralDoubre, H., C. Le Pechoux et T. Le Chevalier. « Adjuvant Treatments in Resectable NSCLC ». Dans Malignant Tumors of the Lung, 215–25. Berlin, Heidelberg : Springer Berlin Heidelberg, 2004. http://dx.doi.org/10.1007/978-3-642-18698-1_19.
Texte intégralRamírez, J. L., M. F. Salazar, J. Gupta, J. M. Sánchez, M. Taron, M. Sänchez-Ronco, Vicente Alberola et R. de las Peñas. « Methylation Patterns and Chemosensitivity in NSCLC ». Dans New trends in cancer for the 21st century, 195–209. Dordrecht : Springer Netherlands, 2006. http://dx.doi.org/10.1007/978-1-4020-5133-3_17.
Texte intégralBlackhall, Fiona H. « Strategies in ALK Rearranged NSCLC Patients ». Dans New Therapeutic Strategies in Lung Cancers, 147–56. Cham : Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-06062-0_10.
Texte intégralLouie, Brian E., et Eric Vallières. « Minimally Invasive Surgery for Early NSCLC ». Dans New Therapeutic Strategies in Lung Cancers, 27–32. Cham : Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-06062-0_3.
Texte intégralPisters, Katherine. « Adjuvant and Neoadjuvant Therapy of NSCLC ». Dans Lung Cancer, 139–59. Totowa, NJ : Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-524-8_6.
Texte intégralTsao, Anne S., et Jack A. Roth. « Novel and Emerging Agents in NSCLC ». Dans Lung Cancer, 464–78. Hoboken, NJ, USA : John Wiley & Sons, Inc., 2014. http://dx.doi.org/10.1002/9781118468791.ch30.
Texte intégralDas, Millie, et Heather Wakelee. « Anti-Angiogenic Agents in Metastatic NSCLC ». Dans Lung Cancer, 527–40. Hoboken, NJ, USA : John Wiley & Sons, Inc., 2014. http://dx.doi.org/10.1002/9781118468791.ch34.
Texte intégralActes de conférences sur le sujet "NSCLP"
Rauthan, Amit, Poonam Patil, Rajashree Aswath, Nitin Yashas et Gaurav Ningade. « Immunotherapy in Patients with Lung Cancer with Driver Mutations : A Single-Centre Experience ». Dans Annual Conference of Indian Society of Medical and Paediatric Oncology (ISMPO). Thieme Medical and Scientific Publishers Pvt. Ltd., 2021. http://dx.doi.org/10.1055/s-0041-1735365.
Texte intégralBenammar, Sarra, Fatima Mraiche, Jensa Mariam Joseph et Katerina Gorachinova. « Glucose and Transferrin Liganded PLGA Nanoparticles Internalization in Non-Small Lung Cancer Cells ». Dans Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0227.
Texte intégralAlam, Mohammed. « A Decision Analytical Model Investigating Cost-Effectiveness of Erlotinib ». Dans Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0145.
Texte intégralGelbke, C. Konrad. « FRIB/NSCL Laboratory Update ». Dans Sixth International Conference on Fission and Properties of Neutron-Rich Nuclei (ICFN6). WORLD SCIENTIFIC, 2017. http://dx.doi.org/10.1142/9789813229426_0030.
Texte intégralOllosi, Stephen L., Margaret Soucheray, Jeffrey Becker, Ines Pulido, Annika Dalheim, Fatima Al-Shahrour, Wei Qui et al. « Abstract 20 : Inhibition of mutant EGFR in NSCLC promotes endothelin-1-mediated NSCLC disease progression and angiogenesis ». Dans Proceedings : AACR Annual Meeting 2018 ; April 14-18, 2018 ; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-20.
Texte intégralShostak, E., R. Liberman et D. Riker. « Stage I NSCLC : Risk Factors for Recurrence. » Dans American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a1107.
Texte intégralPavicevic, R., et G. Bubanovic. « ERCC1 and RRM1 Expression in Resected NSCLC. » Dans American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a2679.
Texte intégralWu, Yi-Long, et Robert van den Heuvel. « Sugemalimab offers PFS benefits for unresectable NSCLC ». Dans IASLC 2022 World Conference on Lung Cancer, sous la direction de Yi-Long Wu et Rachel Giles. Baarn, the Netherlands : Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/675f3ee0.
Texte intégralMolina-Pinelo, Sonia, Gabriel Gutierrez-Pozo, Maria D. Pastor, Marta Hergueta, Gema Moreno-Bueno, Rocio Garcia-Carbonero, Ana BS Nogal et al. « Abstract 5305 : Transcriptionalregulation by microRNAs in NSCLC. » Dans Proceedings : AACR 104th Annual Meeting 2013 ; Apr 6-10, 2013 ; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-5305.
Texte intégralvan den Heivel, Robert. « Confirmatory mediastinoscopy not needed in resectable NSCLC ». Dans ERS International Congress 2022, sous la direction de Richard Dekhuijzen. Baarn, the Netherlands : Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/5e8370b2.
Texte intégralRapports d'organisations sur le sujet "NSCLP"
Dawson, W., J. Boles et K. Le Galloudec. NSLP-Final Report-Draft2022. Office of Scientific and Technical Information (OSTI), février 2022. http://dx.doi.org/10.2172/1860931.
Texte intégralSherrill, Bradley, et Alexandra Gade. Operation of GRETINA at NSCL. Office of Scientific and Technical Information (OSTI), décembre 2017. http://dx.doi.org/10.2172/1427801.
Texte intégralYoung, Jamey D., et Young M. Whang. Targeting Redox Homeostasis in LKB1-deficient NSCLC. Fort Belvoir, VA : Defense Technical Information Center, septembre 2014. http://dx.doi.org/10.21236/ada614534.
Texte intégralPeng, Yinglong, Jinwei Chen, Ziyan Wang, Yihui Cao et Jie Zhao. A Systematic Review and meta-analysis of the efficacy of immunotherapy in the treatment of non-small cell lung cancer. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, juin 2022. http://dx.doi.org/10.37766/inplasy2022.6.0094.
Texte intégralStiemerling, M., H. Tschofenig, C. Aoun et E. Davies. NAT/Firewall NSIS Signaling Layer Protocol (NSLP). RFC Editor, octobre 2010. http://dx.doi.org/10.17487/rfc5973.
Texte intégralFreire, Mariana, Diana Martins, Maria Filomena Botelho et Fernando Mendes. Biomarkers of resistance mechanisms in innovative lung cancer treatments - A systematic Review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, septembre 2022. http://dx.doi.org/10.37766/inplasy2022.9.0011.
Texte intégralWinkles, Jeffrey A. GrB-TWEAK : A Potential Novel Biologic for NSCLC Therapy. Fort Belvoir, VA : Defense Technical Information Center, septembre 2015. http://dx.doi.org/10.21236/ada624531.
Texte intégralOuyang, Zhiqiang, Qian Li, Guangrong Zheng, Tengfei Ke, Jun Yang et Chengde Liao. Radiomics for predicting tumor microenvironment phenotypes in non-small cell lung cance : A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, septembre 2022. http://dx.doi.org/10.37766/inplasy2022.9.0060.
Texte intégralManner, J., G. Karagiannis et A. McDonald. NSIS Signaling Layer Protocol (NSLP) for Quality-of-Service Signaling. RFC Editor, octobre 2010. http://dx.doi.org/10.17487/rfc5974.
Texte intégralSeverin, Gregory, E. Paige Abel et Hannah Clause. Closeout Report : Rare Isotope Generators at the NSCL and FRIB. Office of Scientific and Technical Information (OSTI), janvier 2022. http://dx.doi.org/10.2172/1837939.
Texte intégral